Evidence map›Paper›PMID 41660217›Full record

ArticleClinical and experimental vaccine research2026

Targeting intestinal microbiota with

Chloé Crouzillac, Méline Onzon, Grégory Unique, Grégory Chambon, Nicolas Barnich, Nicolas Bourgne, Elisabeth Billard

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental vaccine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chloé CrouzillacUniversité Clermont Auvergne, Inserm UMR 1071, INRAE USC 1382, M2iSH, Clermont-Ferrand, France.ORCID https://orcid.org/0009-0005-8884-8587
Méline OnzonUniversité Clermont Auvergne, Inserm UMR 1071, INRAE USC 1382, M2iSH, Clermont-Ferrand, France.ORCID https://orcid.org/0009-0001-3536-5603
Grégory UniqueNeobiosys, Le Broc, France.ORCID https://orcid.org/0009-0005-5857-9507
Grégory ChambonNeobiosys, Le Broc, France.ORCID https://orcid.org/0009-0002-5930-1337
Nicolas BarnichUniversité Clermont Auvergne, Inserm UMR 1071, INRAE USC 1382, M2iSH, Clermont-Ferrand, France.ORCID https://orcid.org/0000-0001-9465-7844
Nicolas BourgneNeobiosys, Le Broc, France.ORCID https://orcid.org/0009-0009-8882-8008
Elisabeth BillardUniversité Clermont Auvergne, Inserm UMR 1071, INRAE USC 1382, M2iSH, Clermont-Ferrand, France.ORCID https://orcid.org/0000-0002-6066-4584

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intestinal microbiota plays a critical role in shaping host immune responses to pathogens and vaccines. Dextran sulfate sodium-treated mice showed reduced vaccinal response following prime-boost immunization with purified ovalbumin, as confirmed by decreased specific immunoglobulin (Ig)G and IgM, confirming the negative impact of dysbiosis and associated inflammation. Two probiotic strains were selected,

Indexed as

Bifidobacterium breveHafnia alveiInfluenza vaccineMicrobiotaProbiotic

Identifiers

PMID41660217
PMCPMC12876920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.